These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 29955526)

  • 41. Daclizumab for relapsing remitting multiple sclerosis.
    Liu J; Wang LN; Zhan S; Xia Y
    Cochrane Database Syst Rev; 2013 Dec; (12):CD008127. PubMed ID: 24363032
    [TBL] [Abstract][Full Text] [Related]  

  • 42. An update on new and emerging therapies for relapsing-remitting multiple sclerosis.
    Weinstock-Guttman B
    Am J Manag Care; 2013 Nov; 19(17 Suppl):s343-54. PubMed ID: 24494635
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Novel and imminently emerging treatments in relapsing-remitting multiple sclerosis.
    Oh J; O'Connor PW
    Curr Opin Neurol; 2015 Jun; 28(3):230-6. PubMed ID: 25887773
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis.
    Neuberger EE; Abbass IM; Jones E; Engmann NJ
    Neurol Ther; 2021 Jun; 10(1):183-196. PubMed ID: 33244713
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Burden of relapsing-remitting multiple sclerosis on workers in the US: a cross-sectional analysis of survey data.
    Nicholas JA; Electricwala B; Lee LK; Johnson KM
    BMC Neurol; 2019 Oct; 19(1):258. PubMed ID: 31660897
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study.
    Naismith RT; Wolinsky JS; Wundes A; LaGanke C; Arnold DL; Obradovic D; Freedman MS; Gudesblatt M; Ziemssen T; Kandinov B; Bidollari I; Lopez-Bresnahan M; Nangia N; Rezendes D; Yang L; Chen H; Liu S; Hanna J; Miller C; Leigh-Pemberton R
    Mult Scler; 2020 Nov; 26(13):1729-1739. PubMed ID: 31680631
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Summarizing Patient Preferences for the Competitive Landscape of Multiple Sclerosis Treatment Options.
    Jonker MF; Donkers B; Goossens LMA; Hoefman RJ; Jabbarian LJ; de Bekker-Grob EW; Versteegh MM; Harty G; Wong SL
    Med Decis Making; 2020 Feb; 40(2):198-211. PubMed ID: 32065023
    [No Abstract]   [Full Text] [Related]  

  • 48. Advances in oral immunomodulating therapies in relapsing multiple sclerosis.
    Derfuss T; Mehling M; Papadopoulou A; Bar-Or A; Cohen JA; Kappos L
    Lancet Neurol; 2020 Apr; 19(4):336-347. PubMed ID: 32059809
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study.
    Gold R; Radue EW; Giovannoni G; Selmaj K; Havrdova E; Stefoski D; Sprenger T; Montalban X; Cohan S; Umans K; Greenberg SJ; Ozen G; Elkins J
    BMC Neurol; 2016 Jul; 16():117. PubMed ID: 27461166
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Study design of PANGAEA 2.0, a non-interventional study on RRMS patients to be switched to fingolimod.
    Ziemssen T; Kern R; Cornelissen C
    BMC Neurol; 2016 Aug; 16():129. PubMed ID: 27502119
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data.
    Bell C; Graham J; Earnshaw S; Oleen-Burkey M; Castelli-Haley J; Johnson K
    J Manag Care Pharm; 2007 Apr; 13(3):245-61. PubMed ID: 17407391
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Use of rituximab in adults with relapsing-remitting multiple sclerosis: a systematic literature review.
    Siddiqui MK; Singh B; Attri S; Veraart C; Harty G; Wong SL
    Curr Med Res Opin; 2020 May; 36(5):809-826. PubMed ID: 32129684
    [No Abstract]   [Full Text] [Related]  

  • 53. Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis.
    Li H; Hu F; Zhang Y; Li K
    J Neurol; 2020 Dec; 267(12):3489-3498. PubMed ID: 31129710
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mitoxantrone for multiple sclerosis.
    Martinelli Boneschi F; Vacchi L; Rovaris M; Capra R; Comi G
    Cochrane Database Syst Rev; 2013 May; (5):CD002127. PubMed ID: 23728638
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: the DEFINE study.
    Kappos L; Gold R; Arnold DL; Bar-Or A; Giovannoni G; Selmaj K; Sarda SP; Agarwal S; Zhang A; Sheikh SI; Seidman E; Dawson KT
    Mult Scler; 2014 Feb; 20(2):243-52. PubMed ID: 24150779
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing-remitting multiple sclerosis.
    Siddiqui MK; Khurana IS; Budhia S; Hettle R; Harty G; Wong SL
    Curr Med Res Opin; 2018 Aug; 34(8):1361-1371. PubMed ID: 29149804
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Rapid foot-tapping but not hand-tapping ability is different between relapsing-remitting and progressive multiple sclerosis.
    Sato S; Lim J; Miehm JD; Buonaccorsi J; Rajala C; Khalighinejad F; Ionete C; Kent JA; van Emmerik REA
    Mult Scler Relat Disord; 2020 Jun; 41():102031. PubMed ID: 32172213
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Epidemiology, characteristics and treatment of patients with relapsing remitting multiple sclerosis and incidence of high disease activity: Real world evidence based on German claims data.
    Ohlmeier C; Gothe H; Haas J; Osowski U; Weinhold C; Blauwitz S; Schmedt N; Galetzka W; Berkemeier F; Tackenberg B; Stangel M
    PLoS One; 2020; 15(5):e0231846. PubMed ID: 32357176
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Peginterferon beta-1a versus other self-injectable disease-modifying therapies in the treatment of relapsing-remitting multiple sclerosis in Scotland: a cost-effectiveness analysis.
    Hernandez L; Guo S; Toro-Diaz H; Carroll S; Syed Farooq SF
    J Med Econ; 2017 Mar; 20(3):228-238. PubMed ID: 27730845
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ponesimod: An Oral Second-Generation Selective Sphingosine 1-Phosphate Receptor Modulator for the Treatment of Multiple Sclerosis.
    Alnaif A; Oiler I; D'Souza MS
    Ann Pharmacother; 2023 Aug; 57(8):956-965. PubMed ID: 36514282
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.